Skip to main content
OpenTrials
Completed

NCT Number: NCT03077282

Safety of Prasaprohyai 95%Ethanolic Extract Capsules in Healthy Volunteer

To investigate the safety of Prasaprohyai 95% ethanolic extract at doses of 100 mg and 200 mg for for 6 weeks. (Clinical Trial phase I)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Thammasat university

Khlong Luang, Changwat Pathum Thani, 12120, Thailand

About this study

Sample size Group 1 (100mg/meal) = 6 female, 6 male Group 2 (200mg/meal) = 6 female, 6 male

Volunteers will be divided into 2 groups. One will take Prasaprohyai 95% ethanolic extract capsules at a dose of 100 mg three times a day before meals and the other take Prasaprohyai 95% ethanolic extract capsule at a dose of 200 mg 3 times a day before meals for six weeks. After that, they will cease using the drug for 2 weeks (wash out period). All volunteers will be followed up in the third week, sixth week and eighth week to evaluate the safety of the medicines. The researcher will record data such as age, career, BMI, vital signs, signs and symptoms. Safety will be monitored by hematology tests such as liver function test, renal function test, lipid profile and blood sugar.

The first step in this research will be to study group 1 (100 mg). If it proves safe, the group 2 (200 mg) will be studied.

The data gathered will be evaluated using statistical software. The results are in the form of mean ± standard deviation. The study will be planned as repeated measured ANOVA or Friedman's test in order to evaluate differences between groups, accompanied by using paired t-test or Wilcoxon's test in order to evaluate differences within groups. A significance level of p < 0.05 will be considered statistically significant.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1) Age in range 20-60 years old.
  • 2) Healthy, or don't have serious medical conditions such as congestive heart disease, liver and renal dysfunction, uncontrolled hypertension, severe asthma, tuberculosis, HIV in the previous month before being recruited in the study, using history taking and complete physical examination and laboratory result.
  • 3) Do not taking a medicine constantly.
  • 4) Female not pregnant or lactating (non menopause woman will have a pregnancy test. Time since first day of last menstruation 28-35 days).
  • 5) Participant and agreement to follow the instructions for 8 weeks.
  • 6) Not a participant in another study.

Exclusion criteria

  • 1) Allergic reactions to Prasaprohyai medications.

Treatment and study plan

Prasaprohyai

Drug

Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals

Primary outcomes

  1. Changes of Hematology test

    Time frame: week0, week3, week6 and week8

    All volunteers will receive a hematology test to check renal function, liver function, lipid profile, glucose, complete blood count

Secondary outcomes

  1. Diary note

    Time frame: Everyday until week8 after took Prasaprohyai

    All volunteers will keep a diary of all symptoms and drugs used during the study

Sponsors and collaborators

Lead sponsor

Thammasat University

Other

Collaborators

  • Thai Traditional Medical Knowledge Fund

Registry information

Official study title

Quality Control and Safety of Prasaprohyai 95%Ethanolic Extract Capsules in Healthy Volunteer

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Mar 10, 2017
Registry last updated
Jun 26, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.